CARDIOVASCULAR COMPLICATIONS RISK AND VASCULAR AGE DYNAMICS IN LONG-TERM TREATMENT OF ARTERIAL HYPERTENSION

Aim. To evaluate the possibility for the novel scores implementation in everyday management by perindopril/amlodipine in arterial hypertension patients of high and very high risk.

Material and methods. Totally, 30 patients included, with AH of high and very high risk (12 males, 18 females) at the age 57,7±9,3 y.o., who, after the in-patient management of non-controlled AH by fixed combination of perindopril/amlodipine doses 10/5, 5/10, 10/10 mg, respectively, were treated and followed up for the next 2 years (with additional control in 1 year). During this period there was control of BP dynamics, intervisit variability of SBP/DBP, adherence to treatment, some of hemodynamics values (by EchoCG), lipids, creatinin and glucose of blood. Based on the proposed new expert systems (ASCORE scale, “vascular age” assessment scale) a clinician evaluated the dynamics of individual risk of cardiovascular complications and the “vascular age”.

Results. The outpatients had stage III AH, of those grade 2 AH was diagnosed in 26,7%, and grade3 in 73,3%. In one year of treatment by perindopril/amlodipine in office visit the level of SBP/DBP was 162,8±7,7/91,5±2,4 mmHg; adherence to treatment — 63,4%. During the second year patients adhered to clinicians recommendation, with the target BP levels achieved (adherence 83,4%). There was significant decrease of intervisit variability of SBP (with the baseline 11,6±1,4 mmHg at in-patient and to 4,3±0,2 mmHg in 2 years of outpatient treatment; p<0,001).Lipid spectrum values and glucose decreased significantly. Probability of 5-year risk of cardiovascular complications (CVC) decreased from 16,1±1,1% (in-patient) to 9,2±2,0% (p<0,01) and 4,4±0,7% (p<0,01) in 1 and 2 years, respectively. The “vascular age” during admittance was 14,4 years higher than real (passport), and in 2 years the values of passport age and VS overlapped (p<0,01).

Conclusion. In real-practice circumstances we tested new European expert systems: 5-year risk score for cardiovascular events, and assessment of “vascular age” by SCORE, which demonstrated the probability of CVC risk decline and confirmed the concept of “vascular age” decrease under influence of effective antihypertension therapy. The fixed combination of perindopril/amlodipine, used during two years, showed clinical effectiveness in former non-controlled patients with AH, decreased the intervisit variability of BP, decreased individual risk of CVC and increased adherence to treatment.

1. 2013 ESH/ESC GUIDELINES for the management of arterial hypertension. Russian Journal of Cardiology. 2014; (1): 7-94. Russian. DOI:10.15829/1560-4071-2014-1-7-94. (Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Российский кардиологический журнал. 2014; (1): 7-94. DOI:10.15829/1560-4071-2014-1-7-94).

2. Chazova IE, Oschepkova EV, Zhernakova EV. Diagnosis and treatment of arterial hypertension. Clinical guidelines 2013. Cardiology Bulletin 2015; 1: 3-30. Russian (Чазова И.Е., Ощепкова Е. В., Жернакова Ю. В. Диагностика и лечение артериальной гипертонии. Клинические рекомендации 2013. Кардиологический вестник 2015; 1:3-30).

3. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation often-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 4: 987-1003.

4. D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation 2008; 117: 743-53.

5. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335: 136-9.

6. Shalnova SA, Kalinina AM, Deyev AD, et al. The Russian ORISKON expert system — Assessment of RISK of the Main Noninfectious diseases. Cardiovascular Therapy and Prevention 2013; 12 (4): 51-5. Russian (Шальнова С. А., Калинина А. М., Деев А. Д., Пустеленин А. В. Российская экспертная система ОРИСКОН — Оценка РИСКа Основных Неинфекционных заболеваний. Кардиоваскулярная терапия и профилактика 2013; 12 (4): 51-5).

7. Prieto-Merino D, Dobson J, Gupta AK, et al. ASCORE: an up-todate cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. J. Hum. Hypertens 2013; 27(8): 492-6.

8. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005; 366(948): 895-906.

9. Karpov YuA, Sorokin EV. Influence of the combined hypotensive therapy on risk of cardiovascular complications and vascular age: results of the multicenter open research ADVANTAGE. Atmosphere. News of a cardiology of 2015; 3: 18-26. Russian (Карпов Ю. А., Сорокин Е. В. Влияние комбинированной гипотензивной терапии на риск сердечнососудистых осложнений и сосудистый возраст: результаты многоцентрового открытого исследования ADVANTAGE. Атмосфера. Новости кардиологии 2015; 3: 18-26).

10. Pharmakoepidemiologiya of an arterial Hypertension in Russia: the analysis of commitment of doctors (by results of a research PYTHAGORAS IV). Systemic Hypertensions 2015; 15(1): 19-25. Russian (Фармакоэпидемиология артериальной гипертонии в России: анализ приверженности врачей (по результатам исследования ПИФАГОР IV). Системные гипертензии 2015; 15(1): 19-25).

11. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation . Eur. Heart J 2010; 31: 2351-8.

12. Logacheva IV, Safronova VB Maximov NI, Baranova SP. Practice of maintaining inpatients with an uncontrollable arterial hypertension. Russ J Cardiol 2014; 4(108): 75-81. Russian (Логачева И. В., Сафронова В. В. Максимов Н. И., Баранова С. П. Практика ведения стационарных больных с неконтролируемой артериальной гипертонией. Российский кардиологический журнал 2014; 4(108): 75-81).

13. Shalnova SA. Epidemiology of arterial hypertension in Russia: patient’s portrait. Arterial hypertension 2008; 2(2): 5-10. Russian (Шальнова С. А. Эпидемиология артериальной гипертензии в России: портрет больного. Артериальная гипертензия 2008; 2(2): 5-10).

14. Groenewegen K, den Ruijter H, Pasterkamp G, et al. Vascular age to determine cardiovascular disease risk: a systematic review of its concepts, definitions, and clinical applications. Eur. J. Prev. Cardiol 2015; pii: 2047487314566999. [Epub ahead of print].

15. Gupta AK, Arshad S, Poulter NR, et al. Review Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407